EUVIMEDEUVIMED entdecken
Crossref

Integrated bioinformatics and multi-omics reveal Astragalus extract’s gut-kidney axis mechanism in hyperuricemic nephropathy via purine metabolism

Tingli Qu, Nan Zhang, Junjie Cai, Chen Li, Yue Zhang, Xinxue Xu, Shuai Zhang, Wangwei Lv, Taigang Liang

Phytomedicine · 2025-10 · 146 · 157121

DOI: 10.1016/j.phymed.2025.157121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025-10. Verfasst von Tingli Qu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shanxi Medical University, No.56, Xinjian south Road, Taiyuan 030001, Shanxi, PR China; Medicinal Basic Research Innovation Cente…. Hauptthemen laut MEDLINE: Hyperuricemia, Purines, Kidney Diseases, Astragalus Plant. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Shanxi Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Astragalus has demonstrated clinical efficacy in treating renal diseases. However, its therapeutic potential in hyperuricemic nephropathy (HN) remains underexplored. PURPOSE: This study explores the therapeutic mechanisms of Astragalus aqueous extract (AAE) in HN via gut-kidney axis-mediated regulation of purine metabolism using bioinformatics and multi-omics approaches. STUDY DESIGN: Integrated bioinformatics and multi-omics reveal the molecular mechanism by which AAE treats hyperuricemic nephropathy through gut-kidney axis-mediated regulation of purine metabolism. METHODS: An HN rat model was established to assess AAE's therapeutic effects via biochemical analysis, histological staining, and network pharmacology to identify key bioactive components and targets. Renal and fecal metabolomics, 16S rRNA sequencing, and metabolite analyses provided mechanistic insights, while molecular docking, molecular dynamics (MD) simulations, immunohistochemistry (IHC), and real-time PCR (RT-PCR) validated findings. RESULTS: AAE alleviated HN-induced renal tubular injury and reduced biochemical markers and proinflammatory cytokines. Network pharmacology identified calycosin-7-O-β-d-glucoside (CAL), kumatakenin, isorhamnetin, and astragalin as potential bioactive components. Metabolomics revealed that AAE modulated 119 renal and 306 intestinal differential metabolites, with purine metabolism as the core perturbed pathway. Moreover, 16S rRNA sequencing showed AAE increased Firmicutes/Bacteroidetes (F/B) ratios, enhanced Lactobacillus abundance, and promoted short-chain fatty acid (SCFA) biosynthesis. Docking and MD simulations confirmed that the binding free energies of active ingredients such as CAL to xanthine dehydrogenase (XDH) were all significantly lower than that of xanthine, and XDH, myeloperoxidase (MPO) and hypoxanthine phosphoribosyltransferase 1 Gene (HPRT1) mRNA expressions in renal were significantly decreased after the intervention. CONCLUSION: AAE reshaped renal and intestinal metabolic networks and modulated gut microbiota and SCFA profiles. It regulated uric acid metabolism primarily by balancing intestinal microbiota-mediated purine metabolism and inhibiting XDH, MPO, HPRT1 activity. This study provides a molecular basis for traditional Chinese medicine (TCM) analysis in HN through multi-target integration of "gut-kidney axis".

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaPurinesKidney DiseasesAstragalus PlantPlant ExtractsAnimalsMaleRatsKidneyMolecular Docking SimulationComputational BiologyGastrointestinal MicrobiomeRats, Sprague-DawleyDrugs, Chinese HerbalMetabolomicsMultiomics

Stichwörter der Autor:innen

16S rRNA sequencingAstragalus aqueous extractHyperuricemia nephropathyMetabolomicsMolecular dynamics simulationNetwork pharmacology

Substanzen

PurinesPlant ExtractsDrugs, Chinese Herbal

Autor:innen und Institutionen

  • School of Pharmacy, Shanxi Medical University, No.56, Xinjian south Road, Taiyuan 030001, Shanxi, PR China; Medicinal Basic Research Innovation Center of Chronic Kidney Disease, Ministry of Education, Shanxi Medical Uni…
  • School of Pharmacy, Shanxi Medical University, No.56, Xinjian south Road, Taiyuan 030001, Shanxi, PR China.
  • Shanxi Huakang Pharmaceutical Co., Ltd., No.78, East Street, Wanrong County, Yuncheng 044200, Shanxi, PR China.
  • School of Pharmacy, Shanxi Medical University, No.56, Xinjian south Road, Taiyuan 030001, Shanxi, PR China. Electronic address: ltaigang@163.com.

Förderung

  • Shanxi Medical University

Zitieren

APA

Qu, T., Zhang, N., Cai, J., Li, C., Zhang, Y., Xu, X., Zhang, S., Lv, W., & Liang, T. (2025). Integrated bioinformatics and multi-omics reveal Astragalus extract’s gut-kidney axis mechanism in hyperuricemic nephropathy via purine metabolism. Phytomedicine, 146, 157121. https://doi.org/10.1016/j.phymed.2025.157121

Vancouver

Qu T, Zhang N, Cai J, Li C, Zhang Y, Xu X, et al. Integrated bioinformatics and multi-omics reveal Astragalus extract’s gut-kidney axis mechanism in hyperuricemic nephropathy via purine metabolism. Phytomedicine. 2025;146:157121. doi:10.1016/j.phymed.2025.157121

BibTeX
@article{Qu2025,
  author = {Qu, Tingli and Zhang, Nan and Cai, Junjie and Li, Chen and Zhang, Yue and Xu, Xinxue and Zhang, Shuai and Lv, Wangwei and Liang, Taigang},
  title = {Integrated bioinformatics and multi-omics reveal Astragalus extract’s gut-kidney axis mechanism in hyperuricemic nephropathy via purine metabolism},
  journal = {Phytomedicine},
  year = {2025},
  volume = {146},
  pages = {157121},
  doi = {10.1016/j.phymed.2025.157121}
}
Kostenlos starten →